Business Wire · Mar 2026
Announcement of a collaboration with Rosebud, Kantify, and Incite to evaluate off-target chemotherapeutic toxicities in patient-specific heart, liver, and kidney organoids.
Growing micro-organs to find new drugs
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Rosebud Biosciences is an early-stage biotechnology startup developing mutation-specific human organoid models to accelerate drug discovery for rare pediatric genetic diseases. It partners with pharma/biotech customers to screen therapies and also pursues internal discovery for rare diseases with no existing treatments.
Primary product
An AI- and robotics-enabled organoid drug-discovery platform built from patient-specific hiPSC-derived 2.5D organoids
Founded
2020
Headquarters
San Carlos, California, United States
Team size
1-10
Industry
Biotechnology
Sub-industry
Organoid-based drug discovery for rare pediatric genetic diseases
Offices
Open Positions
14 jobs at Rosebud Biosciences
Implementation Strategist
On-siteSales OpsCalifornia6mo ago
On-site